Literature DB >> 18423425

Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell.

Ruth Sharf1, Maysa Sarhan, Ralph J Dileone.   

Abstract

BACKGROUND: The lateral hypothalamic neuropeptide orexin (or hypocretin) is implicated in drug addiction. Although a role for orexin has been shown in reward and dependence, the molecular and neural mechanisms are unclear. We investigated the mechanism and neuroanatomic basis of orexin's role in morphine withdrawal.
METHODS: C57BL/6J mice received chronic morphine followed by naloxone (0 or 1 mg/kg, subcutaneous) to precipitate withdrawal. Before naloxone, mice received SB-334867 (0 or 20 mg/kg, intraperitoneal), an orexin 1 receptor (Ox1r) antagonist. Using immunohistochemistry, c-Fos, a marker of cell activation, was quantified in the nucleus accumbens (Acb), lateral hypothalamus (LH), ventral tegmental area (VTA), and locus coeruleus (LC). Retrograde tracing with fluorogold (FG) was performed to determine whether orexin neurons project directly to the Acb.
RESULTS: SB-334867 before naloxone significantly attenuated withdrawal symptoms. Withdrawal was accompanied by an increase in c-Fos expression in the Acb shell (AcbSh), which was reduced by SB-334867 but had no effect on the VTA or the LC. Morphine withdrawal increased c-Fos expression in the dorsomedial (DMH) and perifornical (PFA) regions but not in the lateral region of the LH (LLH). Orexin neurons do not appear to form direct connections with Acb neurons.
CONCLUSIONS: Altogether, these data demonstrate that orexin, acting via Ox1r, is critical for the expression of morphine withdrawal. AcbSh activation during withdrawal is dependent on Ox1r function and is likely mediated by indirect action of LH orexin neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423425      PMCID: PMC2529153          DOI: 10.1016/j.biopsych.2008.03.006

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  60 in total

Review 1.  The hypocretins: setting the arousal threshold.

Authors:  J Gregor Sutcliffe; Luis de Lecea
Journal:  Nat Rev Neurosci       Date:  2002-05       Impact factor: 34.870

2.  Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal.

Authors:  Dan Georgescu; Venetia Zachariou; Michel Barrot; Michihiro Mieda; Jon T Willie; Amelia J Eisch; Masashi Yanagisawa; Eric J Nestler; Ralph J DiLeone
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

3.  SB-334867-A antagonises orexin mediated excitation in the locus coeruleus.

Authors:  E M Soffin; M L Evans; C H Gill; M H Harries; C D Benham; C H Davies
Journal:  Neuropharmacology       Date:  2002-01       Impact factor: 5.250

4.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

5.  Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement.

Authors:  M S Duxon; J Stretton; K Starr; D N Jones; V Holland; G Riley; J Jerman; S Brough; D Smart; A Johns; W Chan; R A Porter; N Upton
Journal:  Psychopharmacology (Berl)       Date:  2001-01-01       Impact factor: 4.530

6.  Differential expression of orexin receptors 1 and 2 in the rat brain.

Authors:  J N Marcus; C J Aschkenasi; C E Lee; R M Chemelli; C B Saper; M Yanagisawa; J K Elmquist
Journal:  J Comp Neurol       Date:  2001-06-18       Impact factor: 3.215

7.  Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area.

Authors:  J Fadel; A Y Deutch
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

8.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 9.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness.

Authors:  J T Willie; R M Chemelli; C M Sinton; M Yanagisawa
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

10.  Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons.

Authors:  Judith Joyce Balcita-Pedicino; Susan R Sesack
Journal:  J Comp Neurol       Date:  2007-08-10       Impact factor: 3.215

View more
  49 in total

Review 1.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

2.  Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

Authors:  James R Shoblock; Natalie Welty; Leah Aluisio; Ian Fraser; S Timothy Motley; Kirsten Morton; James Palmer; Pascal Bonaventure; Nicholas I Carruthers; Timothy W Lovenberg; Jamin Boggs; Ruggero Galici
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 3.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 4.  Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity.

Authors:  Angie M Cason; Rachel J Smith; Pouya Tahsili-Fahadan; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Physiol Behav       Date:  2010-03-23

5.  Decrease of inhibitory synaptic currents of locus coeruleus neurons via orexin type 1 receptors in the context of naloxone-induced morphine withdrawal.

Authors:  Mahnaz Davoudi; Hossein Azizi; Javad Mirnajafi-Zadeh; Saeed Semnanian
Journal:  J Physiol Sci       Date:  2018-11-07       Impact factor: 2.781

Review 6.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 7.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 8.  Shining light on wakefulness and arousal.

Authors:  Luis de Lecea; Matthew E Carter; Antoine Adamantidis
Journal:  Biol Psychiatry       Date:  2012-03-20       Impact factor: 13.382

9.  Reduced emotional signs of opiate withdrawal in rats selectively bred for low (LoS) versus high (HiS) saccharin intake.

Authors:  Anna K Radke; Nathan A Holtz; Jonathan C Gewirtz; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2012-12-20       Impact factor: 4.530

Review 10.  The role of hypocretin in driving arousal and goal-oriented behaviors.

Authors:  Benjamin Boutrel; Nazzareno Cannella; Luis de Lecea
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.